Breaking News

IntelGenx, Par Enter Drug Delivery Pact

By Kristin Brooks | January 13, 2014

Par to use oral drug delivery platform for two additional products

IntelGenx Corp. has entered into a development and commercialization agreement with Par Pharmaceutical for two new products using IntelGenx' oral drug delivery platforms. Par has certain exclusive rights to market and sell IntelGenx' products in the U.S. and IntelGenx will receive upfront and milestone payments, as well as a share of the profits upon commercialization. Additional details were not disclosed.
"We are very excited to strengthen our affiliation with Par for the development of two new products," said Dr. Rajiv Khosla, president and chief executive officer of IntelGenx. "We view this new agreement not only as testament to the excellent working relationship that developed between the two companies during development of the Buprenorphine/Naloxone Sublingual Film Product, but also as further validation of our oral delivery platforms and our ability to develop novel products."

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016